Avelumab in Merkel Cell Carcinoma: Prognosis and Treatment for Severe Disease After Avelumab

From General Health Awareness to Targeted Cancer Therapy

Public health communication has traditionally focused on broad preventive measures and awareness of common risk factors, guiding populations toward healthier lifestyles and early detection. This foundational approach has successfully reduced the burden of many diseases. As this heritage evolves, it increasingly intersects with specialized clinical research, where the focus narrows from population-level guidance to individual patient outcomes. One such area involves immune checkpoint inhibitors, which have transformed treatment paradigms for certain malignancies. Among these, Avelumab has emerged as a significant option for managing advanced Merkel cell carcinoma (MCC), a rare but aggressive skin cancer. The transition from general health education to this specific clinical context requires careful consideration of how exposure to therapeutic agents relates to disease prognosis. In occupational settings, particularly for workers in healthcare or pharmaceutical manufacturing, the potential for unintended exposure to such biologics introduces a distinct concern. While the primary focus remains on patient treatment, the occupational exposure risk to Avelumab and its implications for MCC prognosis warrants attention. This pivot from general health awareness to a targeted occupational concern underscores the need for integrated risk assessment, bridging public health principles with specialized clinical and workplace safety considerations.

Avelumab: Mechanism and Clinical Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are limited (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Treatment Options for Avelumab-Refractory Merkel Cell Carcinoma

In a multicenter study of the prospective skin cancer registry ADOREG, response rates to PD-1/PD-L1 inhibition in metastatic MCC were reported to be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). For avelumab-refractory patients, combined therapy with ipilimumab and nivolumab has been investigated. In a retrospective study at three German academic sites, five patients with metastatic MCC refractory to avelumab were treated with combined ipilimumab and nivolumab; three out of five responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that ipilimumab plus nivolumab can be effective in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings suggest that alternative checkpoint inhibitor combinations may provide benefit after avelumab failure, though data remain limited to small case series.

Immune-Related Adverse Events and Prognostic Considerations

Avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC receiving avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). The hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the need for monitoring for irAEs during avelumab treatment, including rare events such as sarcoidosis reactivation. Regarding prognosis, patients with advanced MCC who progress on avelumab face a poor outlook, as approved systemic therapies in Europe are limited to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). The timeline between avelumab exposure and documented harm varies. In the JAVELIN Merkel 200 trial, objective responses were assessed over the course of treatment, but specific timelines for adverse events were not detailed in the provided evidence. The case of sarcoidosis reactivation occurred during avelumab therapy, with hypercalcemia managed without treatment discontinuation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory disease, the timeline to progression is not explicitly stated, but approximately half of patients progress on initial immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Adequacy of warnings regarding avelumab and MCC is supported by its approval based on clinical trial data and the inclusion of immune-related adverse events in prescribing information. However, the evidence does not provide specific details on the content of warnings or patient counseling materials. The risk of progression despite avelumab therapy is substantial, and patients should be informed about the possibility of refractory disease and the limited subsequent treatment options. Prognosis-related considerations include the aggressive nature of MCC, the potential for durable responses in some patients, and the need for close monitoring for irAEs and disease progression.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Avelumab and how does it work for Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) and works by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells.

What are the treatment options if Merkel cell carcinoma progresses after Avelumab?

For patients with avelumab-refractory MCC, combined therapy with ipilimumab and nivolumab has shown promise in small studies. In a retrospective study, three out of five patients responded to this combination (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study confirmed that ipilimumab plus nivolumab can be effective in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, data remain limited.

What are the common side effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include inflammation of various organs. Rare events such as sarcoidosis reactivation have been reported. Monitoring for irAEs is essential during treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.